Swiss biotech start-up Tolremo says its new methods of cancer treatment are turbo-charging the field. CEO Stefanie Flückiger-Mangual—who likens her company’s treatment to a boxer knocking out an opponent—explains why her start-up benefitted from the “unique Swiss position” when it comes to funding, and how her American counterparts in the biotech industry are struggling. Part of our Swiss Start-up Tour.
